Gastroprotective action of cryopreserved placenta extract under the prophylactic mode of administration
DOI:
https://doi.org/10.32782/2415-8127.2022.65.4Keywords:
cryopreserved placenta extract, gastric ulcer, antiulcer therapy, gastric mucosa, ethanol-prednisolone gastric lesions.Abstract
Introduction. Timely treatment and prevention of peptic ulcer of the stomach and duodenum is not only medical but also social. As a potential gastroprotective agent, our attention was drawn to the cryopreserved extract of human placenta, because the literature convincingly demonstrated that this cryoextract eliminates the ulcerogenic action of nonsteroidal anti-inflammatory drugs, which has a mechanism similar to peptic ulcer disease. The aim of the study was to characterize the gastroprotective activity of cryopreserved placenta extract under the prophylactic regimen of use in the model of ethanol-prednisolone gastric lesions in rats. Materials and methods. The study was performed on 28 male rats weighing 200–220 g. Gastric lesions in rats were simulated by intragastric single administration of prednisolone (20 mg/kg) dissolved in 80.0% ethanol (0.6 ml/100 g body weight). Cryoextracts of the placenta were administered intravenously in a prophylactic mode – 1 time per day for 5 days before the introduction of ethanol-prednisolone mixture. In 24 h. after administration of the mixture, rats were removed from the experiment and the size of the stomach (bloating) and the presence of adhesions with adjacent organs were evaluated macroscopically by the following criteria: erosions and hemographies, hyperemia, edema and mucosal fold disorders. For each group, the percentage of experimental animals was calculated according to these characteristics and the average value of their severity. The values of the ulcer index were calculated for each group. Research results and their discussion. The introduction of ethanol-prednisolone mixture causes erosive ulcerative lesions of the gastric mucosa in 100% of rats The introduction of cryoextract placenta significantly reduced the damaging effect of ulcerogenic mixture on the mucous membrane, advice on the performance of control rats. The severity of antiulcer activity of the studied cryoextract in the prophylactic mode of use is statistically significantly (p<0.05) exceeds the similar effect of esomeprazole. Conclusions. Prophylactic five-day administration of cryopreserved placenta extract is accompanied by a statistically significant (p<0.05) marked gastroprotective effect in a model of ethanol-prednisolone gastric lesions in rats.
References
Bereda G. Peptic Ulcer Disease: Definition, Pathophysiology, and Treatment. Journal of Biomedical and Biological Sciences. 2022;1(2):1–10.
Hladkykh F.V., Stepanuk N.G., Vernygorodsky S.V. Macro- and microscopic study of the effect of 2-phenyl-3-carbetoxy- 4-dimethylaminomethyl-5-oxybenzofuran hydrochloride (vinboron) on gastrotoxicity ibuprofen in experimental rheumatoid arthritis in rats. Path of Science. 2017;10:7001–18. DOI: http://dx.doi.org/10.22178/pos.27-8.
Hladkykh F.V. Anti-inflammatory properties of diclofenac sodium on the background of combined use with cryopreserved placenta extract in the experiment. Problems of cryobiology and cryomedicine. 2021;31(4):364–7. DOI: https://doi.org/10.15407/ cryo31.04.364.
Hladkykh F.V. Antiulcer activity of placental cryoextract in experimental indomethacin-induced ulcerogenesis. Lviv Medical Journal. 2021;27(3–4):67–82. DOI: https://doi.org/10.25040/aml2021.3-4.067.
Hladkykh F.V. Gastrocytoprotective properties of cryopreserved placenta extract in combined action of low temperatures and inhibition of cyclooxygenase. Acta Facultatis Medicae Naissensis. 2022;39(1):48–56. DOI: https://doi.org/10.5937/ afmnai39-33036.
Holtsev A.N., Yurchenko T.N., ed., Blazhko E.V., Bobyreva L.E., Heraskyna L.R., Hryshchenko V.Y., Hubyna-Vakulyk H.Y., Dvornyk Y.L., Evtereva Y.A., Zhdan V.N., Zvarych P.R., Kapustianskaia A.A., Kuzmyna Y.Iu., Lypyna O.V., Lomakova Y.V., Lutsenko N.S., Muryzyna Y.Iu., Plotnykova V.N., Prokopiuk V.Iu., Prokopenko O.S., Reznykova V.A., Strona V.Y., Strona D.V., Tryfanov V.Iu., Feskova A.M., Feskova Y.A., Shepytko V.Y., Shepytko K.V. Placenta: cryopreservation, clinical use. Kharkiv: Brovyn AV; 2013. 268 p.
Pan S.Y., Chan M.K.S., Wong M.B.F., Klokol D., Chernykh V. Placental therapy: An insight to their biological and therapeutic properties. Journal of Medicine and Therapeutics. 2017;1(3):1–6. DOI: http://doi.org/10.15761/JMT.1000118.
Pandey A., Saraswat N., Wal P., Pal R.S., Wal A., Maurya D.M. A detailed review on: recent advances, pathophysiological studies and mechanism of peptic ulcer. Research Journal of Pharmacology and Pharmacodynamics. 2019;11(4):165–70. DOI: https://doi.org/10.5958/2321-5836.2019.00029.6.
Pogozhykh O., Prokopyuk V., Figueiredo C., Pogozhykh D. Placenta and placental derivatives in regenerative therapies: experimental studies, history, and prospects. Stem Cells Int. 2018;2018:1–14. DOI: https://doi.org/10.1155/2018/4837930.
Rybolovlev U.R., Rybolovlev R.S. Dosage of substances for mammals by constants of biological activity. Reports of the USSR Academy of Sciences. 1979;247(6):1513–6.
Satoh H., Akiba Y., Urushidani T. Proton pump inhibitors prevent gastric antral ulcers induced by NSAIDs via activation of capsaicin‑sensitive afferent nerves in mice. Digestive Diseases and Sciences. 2020;65:2580–94. DOI: https://doi.org/10.1007/ s10620-020-06157-x.
Shell E.J. Pathophysiology of peptic ulcer disease. Physician Assistant Clinics. 2021;6(4):603–11. DOI: https://doi. org/10.1016/j.cpha.2021.05.005.
Stefanov O.V. Preclinical studies of drugs: guidelines. Kyiv : Avicenna; 2001. 527 p.
Sverden E., Agreus L., Dunn J.M., Lagergren J. Peptic ulcer disease. British Medical Journal. 2019;367:l5495. DOI: https:// doi.org/10.1136/bmj.l5495.
Vogel H.G. ed. Drug Discovery and Evaluation: Pharmacological Assays Berlin, Heidelberg: Springer Berlin Heidelberg 2008; 2071 p. 16. Wei Xie, Xielin Huang, Renpin Chen, Ruru Chen, Tang Li, Wei Wu, Zhiming Huang. Esomeprazole alleviates the damage to stress ulcer in rats through not only its antisecretory effect but its antioxidant effect by inactivating the p38 MAPK and NF-κB signaling pathways. Drug Design, Development and Therapy. 2019;22(13):2969–84. DOI: http://doi.org/10.2147/DDDT. S193641.
